Abstract: A system including an extraction force transfer coupling link assembly is provided that extracts a cargo from an airborne aircraft with an extraction parachute and then deploys the cargo with a descent parachute. During a normal extraction the link assembly transfers a force from an extraction line to a deployment lanyard that deploys a descent parachute. In the event of a failed extraction, the assembly severs the deployment lanyard and jettisons the extraction parachute. The extraction force transfer coupling link assembly includes an ultra high molecular weight polyethylene rope that has one end of the deployment lanyard braided with the extraction line. The rope acts as both the extraction line for the cargo and the deployment lanyard for the descent parachute. By virtue of the ability to use a single rope, the link assembly is of simple construction and employs pyrotechnic cutters to effect the release of the extraction line and deployment lanyard rather than conventional mechanical interlocks.

Abstract: A user interface can display active and passive content. For example, a camera viewfinder image can be displayed on a screen, as part of a strip, concatenated with one or more other images, for example, images that were previously taken with the camera. A user can cause the viewfinder image and the other images to move together across the screen. This can allow a user to easily examine the other images and the viewfinder image without, for example, switching between different screens in a user interface. Media captured with a device can be associated with a media category by positioning a user interface element near one or more other elements associated with the category.

Abstract: Techniques and tools are described for rendering views of a map in which map metadata elements are layered in 3D space through which a viewer navigates. Layering of metadata elements such as text labels in 3D space facilitates parallax and smooth motion effects for zoom-in, zoom-out and scrolling operations during map navigation. A computing device can determine a viewer position that is associated with a view altitude in 3D space, then render for display a map view based upon the viewer position and metadata elements layered at different metadata altitudes in 3D space. For example, the computing device places text labels in 3D space above features associated with the respective labels, at the metadata altitudes indicated for the respective labels. The computing device creates a map view from points of the placed labels and points of a surface layer of the map that are visible from the viewer position.

Abstract: A device, system, and method for a thin Si solar cell with epitaxial lateral overgrowth (ELO) structure described in may demonstrate higher open circuit voltage are disclosed herein. An exemplary thin silicon solar cell structure has a p+ silicon substrate. A dielectric layer is disposed over the p+ silicon substrate. One or more trenches are defined within the dielectric layer. A thin n type silicon layer is grown on the p+ silicon substrate within the trench by epitaxial lateral overgrowth wherein a junction area of the solar cell is minimized.

Abstract: This invention relates to a high efficiency solar cell comprising: (a) a top surface of an anti-reflective coating layer; (b) an engineered photonic crystal material layer, (c) an active photovoltaic layer; (d) a photonic crystals with an integrated diffraction grating; (e) a metallic diffraction grating reflective layer, and (f) a metallic back reflector; whereby normally incident light striking the surface of the solar cell passes through the anti-reflective coating and the engineered photonic crystal material layer and is absorbed by active photovoltaic layer thereby generating electrical energy and obliquely incident light is reflected and diffracted by the engineered photonic crystal material layer, the one dimensional photonic crystal layer, the metallic grating reflective layer and the metallic back reflector to the active photovoltaic layer thereby generating electrical energy.

Abstract: A device, system, and method for solar cell construction and bonding/layer transfer are disclosed herein. An exemplary structure of solar cell construction involves providing a monocrystalline donor absorber layer. A conductive bonding layer bonds the absorber layer to a carrier substrate. A porous layer or ion implant may be used to form the donor absorber layer.

Abstract: A device, system, and method for a silicon germanium solar cell structure. An exemplary silicon germanium solar cell structure has a substrate with a graded buffer layer grown on the substrate. An absorber layer is grown on the graded buffer layer and an emitter layer is grown on the absorber layer. A first junction is provided between the emitter layer and the absorber layer. A second junction may be provided between the substrate and the graded buffer layer.

Abstract: A user interface can display active and passive content. For example, a camera viewfinder image can be displayed on a screen, as part of a strip, concatenated with one or more other images, for example, images that were previously taken with the camera. A user can cause the viewfinder image and the other images to move together across the screen. This can allow a user to easily examine the other images and the viewfinder image without, for example, switching between different screens in a user interface. Media captured with a device can be associated with a media category by positioning a user interface element near one or more other elements associated with the category.

Abstract: Brachytherapy dose attributable to a brachytherapy source is computed for portions of a patient treatment volume corresponding to a pathological target volume and critical structures. Patient image data is accessed to derive a material voxel array. Multiple computation grids are derived. Primary particle fluence is computed for each first grid element using a ray tracing process from which a primary dose and a first scattered particle source are derived. Scattered particle fluence of the first scattered particle source is derived for each second grid element from which a secondary dose is derived. Each first grid element corresponds to a plurality of second grid elements. Primary dose and scattered dose combine to provide total dose at specific volumes. Brachytherapy source models and non-anatomical body surface models may be applied as applicable.

Abstract: There are provided monitors which sense a magnitude of power (and/or energy) being consumed by a facility and which sense a magnitude of power (and/or energy) being produced by at least one energy-producing system. There are provided facilities comprising at least one main panel bus, at least one external power line, at least one energy-producing system, at least one critical load sub-panel bus and at least one monitor which senses a magnitude of power (and/or energy) being consumed by the facility and a magnitude of power (and/or energy) being produced by the at least one energy-producing system. There are provided methods of monitoring power (and/or energy) consumed and power (and/or energy) produced in a facility, and devices which display magnitude of power (and/or energy) being consumed and magnitude of power (and/or energy) being produced in a battery.

Abstract: There are provided monitors which sense a magnitude of power (and/or energy) being consumed by a facility and which sense a magnitude of power (and/or energy) being produced by at least one energy-producing system. There are provided facilities comprising at least one main panel bus, at least one external power line, at least one energy-producing system, at least one critical load sub-panel bus and at least one monitor which senses a magnitude of power (and/or energy) being consumed by the facility and a magnitude of power (and/or energy) being produced by the at least one energy-producing system. There are provided methods of monitoring power (and/or energy) consumed and power (and/or energy) produced in a facility, and devices which display magnitude of power (and/or energy) being consumed and magnitude of power (and/or energy) being produced in a battery.

Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) wherein R, R1, R2, R3, R4, R21, R27, R28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula or other compounds capable of enhancing acetylcholine release with acetylcholinesterase inhibitors.

Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) 1

Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) wherein R, R1, R2, R3, R4, R21, R27, R28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula or other compounds capable of enhancing acetylcholine release with acetylcholinesterase inhibitors.

Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.21, R.sup.27, R.sup.28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula with acetylcholinesterase inhibitors.

Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.21, R.sup.27, R.sup.28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula or other compounds capable of enhancing acetylcholine release with acetylcholinesterase inhibitors.

Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.21, R.sup.27, R.sup.28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula with acetylcholinesterase inhibitors.

Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds of formula I ##STR1## wherein one of Y and Z is N and the other is N, CH, or C-alkyl;X is --O--, --SO.sub.0-2 --, amino, substituted amino, --CO--, --CH.sub.2 --, mono or di-substituted methylene, --CS--, --CONR.sup.20 --, --NR.sup.20 --SO.sub.2 --, --NR.sup.20 CO--, --SO.sub.2 NR.sup.20 --, --CH.dbd.CH--, --C.tbd.C-- or --NHC(O)NH--;R is optionally substituted phenyl, aryl or cycloalkyl, or other substituents as defined in the specification;R.sup.1 and R.sup.21 are H, CN or optionally substituted alkyl, or other substituents as defined in the specification;R.sup.2 is optionally substituted cycloalkyl or piperidyl, or other substituents as defined in the specification; andR.sup.3, R.sup.4, R.sup.5, R.sup.20, R.sup.27 and R.sup.

Abstract: The invention describes a method for determining the BZ-1 receptor activity of a test sample or a potential anxiolytic drug.

Abstract: A method, reagents, and kit for determining the levels of D-1 receptor antagonistic activity of neuroleptic drugs. The method correlates competition between analyte and tritiated R-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol for binding to D-1 receptors in mammalian brain tissue.